Projection of power and events in clinical trials with a time-to-event outcome

被引:5
|
作者
Royston, Patrick [1 ,2 ]
Barthel, Friederike M-S [3 ]
机构
[1] Hub Trials Methodol Res, MRC Clin Trials Unit, London, England
[2] UCL, London, England
[3] GlaxoSmithKline Inc, Oncol Res & Dev, Uxbridge, Middx, England
来源
STATA JOURNAL | 2010年 / 10卷 / 03期
基金
英国医学研究理事会;
关键词
st0013_2; artpep; artbin; artsurv; artmenu; randomized controlled trial; time-to-event outcome; power; number of events; projection; ARTPEP; ART; SAMPLE-SIZE; SURVIVAL;
D O I
10.1177/1536867X1001000306
中图分类号
O1 [数学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 0701 ; 070101 ;
摘要
In 2005, Barthel, Royston, and Babiker presented a menu-driven Stata program under the generic name of ART (assessment of resources for trials) to calculate sample size and power for complex clinical trial designs with a time-to-event or binary outcome. In this article, we describe a Stata tool called ARTPEP, which is intended to project the power and events of a. trial with a time-to-event outcome into the future given patient accrual figures so far and assumptions about event rates and other defining parameters. ARTPEP has been designed to work closely with the ART program and has an associated dialog box. We illustrate the use of ARTPEP with data from a phase III trial in esophageal cancer.
引用
收藏
页码:386 / 394
页数:9
相关论文
共 50 条
  • [41] Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review
    Grady, Connor B.
    Li, Yimei
    Maude, Shannon L.
    Hexner, Elizabeth O.
    Frey, Noelle, V
    Porter, David L.
    Hwang, Wei-Ting
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (04): : 271e1 - 271e13
  • [42] Risk Projection for Time-to-Event Outcome Leveraging Summary Statistics With Source Individual-Level Data
    Zheng, Jiayin
    Zheng, Yingye
    Hsu, Li
    JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2022, 117 (540) : 2043 - 2055
  • [43] Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials
    Bellera, Carine A.
    Pulido, Marina
    Gourgou, Sophie
    Collette, Laurence
    Doussau, Adelaide
    Kramar, Andrew
    Dabakuyo, Tienhan Sandrine
    Ouali, Monia
    Auperin, Anne
    Filleron, Thomas
    Fortpied, Catherine
    Le Tourneau, Christophe
    Paoletti, Xavier
    Mauer, Murielle
    Mathoulin-Pelissier, Simone
    Bonnetain, Franck
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (04) : 769 - 781
  • [44] Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
    Royston, Patrick
    Barthel, Friederike M-S
    Parmar, Mahesh K. B.
    Choodari-Oskooei, Babak
    Isham, Valerie
    TRIALS, 2011, 12
  • [45] Multi-arm multi-stage clinical trials for time-to-event outcomes
    Dixit, Vaidehi
    Mitra, Priyam
    Simonsen, Katy
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2021, 31 (06) : 838 - 851
  • [46] Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials JACC Review Topic of the Week
    Gregson, John
    Sharples, Linda
    Stone, Gregg W.
    Burman, Carl-Fredrik
    Ohrn, Fredrik
    Pocock, Stuart
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (16) : 2102 - 2112
  • [47] Bayesian design of clinical trials using joint models for longitudinal and time-to-event data
    Xu, Jiawei
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    BIOSTATISTICS, 2022, 23 (02) : 591 - 608
  • [48] Retrieved-Dropout-Based multiple imputation for time-to-event data in cardiovascular outcome trials
    He, Jiwei
    Crackel, Roberto
    Koh, William
    Chen, Ling-Wan
    Li, Feng
    Zhang, Jialu
    Rothmann, Mark
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (02) : 234 - 252
  • [49] Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
    Patrick Royston
    Friederike M-S Barthel
    Mahesh KB Parmar
    Babak Choodari-Oskooei
    Valerie Isham
    Trials, 12
  • [50] Bayesian design of clinical trials with multiple time-to-event outcomes subject to functional cure
    Cho, Seoyoon
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2025,